Abstract
Patients with cancer have an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and a high case-fatality rate. The duration of anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies in cancer patients following SARS-CoV-2 infection has not been reported previously. We conducted a longitudinal study at a cancer center in Wuhan, China to determine the duration of the humoral immune response following SARS-CoV-2 infection in cancer patients and to determine factors associated with a short duration (< 6 months) of anti-SARS-CoV-2 immunoglobulin G (IgG). Of 2139 cancer patients screened, 78 with confirmed SARS-CoV-2 infection were included in this study. SARS-CoV-2 IgG antibodies were present for < 6 months in 39.7% of these patients. In addition, patients who received chemotherapy were more likely to have a short duration of anti-SARS-CoV-2 IgG (odds ratio 5.31, 95% confidence interval 1.09-26.02, P < 0.05). Our study suggests that cancer patients, especially those who were receiving chemotherapy, have a shorter anti-SARS-CoV-2 IgG duration following infection and therefore, should be prioritized for vaccination.
【초록키워드】 SARS-CoV-2, IgG, coronavirus, vaccination, antibody, SARS-COV-2 infection, Cancer, Infection, anti-SARS-CoV-2, Chemotherapy, Immunoglobulin, anti-SARS-CoV-2 IgG, SARS-CoV-2 IgG antibody, Patient, Cancer patients, humoral immune response, patients, Odds ratio, cancer patient, Cancer center, acute respiratory syndrome, Factor, 95% confidence interval, increased risk, short duration, Wuhan, China, reported, addition, conducted, receiving, screened, determine, 【제목키워드】 SARS-CoV-2, Duration, Immunoglobulin G, longitudinal, determinant,